Journal: Leukemia

Article Title: A point mutation of zebrafish c-cbl gene in the ring finger domain produces a phenotype mimicking human myeloproliferative disease

doi: 10.1038/leu.2015.154

Figure Lengend Snippet: Increase in HSPCs was dependent on the Flt3 pathway. (a–d) flt3 MO injection attenuated the phenotype of LDD731. (e and f) c-myb staining of zebrafish embryos after treatment with 500 nM Lestaurtinib. (g and h) c-myb staining of embryos after treatment with 100 nM PKC412. (i) CBL mutation decreased FLT3 ubiquitination levels and upregulated mature FLT3. 293T cells were transfected with FLT3 and/or c-CBL constructs as indicated. After lysis, FLT3 was immunoprecipitated, blotted and probed with anti-FLT3 and anti-FK2. (j) Inhibitors were used to treat 293T cells. The cells transfected with FLT3 and c-CBL were treated with or without PKC412 or Lestaurtinib for 24 h. After lysis, protein samples were blotted and probed with FLT3, c-CBL and pFLT3 antibodies.

Article Snippet: FLT3 (fms-like tyrosine kinase 3) inhibitor PKC412 (ref. 22 ) (sc-200691) and Lestaurtinib 23 (sc-218657) with stock concentrations of 10 mM, were purchased from Santa Cruz Biotechnology and stored at − 80 °C.

Techniques: Injection, Staining, Mutagenesis, Ubiquitin Proteomics, Transfection, Construct, Lysis, Immunoprecipitation

Journal: Cancer cell

Article Title: MAST1 drives cisplatin resistance in human cancers by rewiring cRaf independent MEK activation

doi: 10.1016/j.ccell.2018.06.012

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Midostaurin , LC Laboratories , Cat#P-7600; CAS: 120685–11-2.

Techniques: Recombinant, Negative Control, Viability Assay, Kinase Assay, Extraction, Ab Array, Activation Assay, Enzyme-linked Immunosorbent Assay, Reverse Transcription, shRNA, Sequencing, Plasmid Preparation, Software

Journal: ESMO Open

Article Title: European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis

doi: 10.1136/esmoopen-2019-000606

Figure Lengend Snippet: Molecular structure of midostaurin.

Article Snippet: Midostaurin is a multitarget receptor tyrosine kinase inhibitor ( ).

Techniques:

Journal: ESMO Open

Article Title: European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis

doi: 10.1136/esmoopen-2019-000606

Figure Lengend Snippet: Key favourable and unfavourable effects for midostaurin in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy and for patients in complete response followed by midostaurin single agent maintenance therapy for adult patients with newly diagnosed AML who are FLT3 mutation positive (study A2301; cut-off date: 1 April 2015)

Article Snippet: Midostaurin is a multitarget receptor tyrosine kinase inhibitor ( ).

Techniques: Mutagenesis, Infection

Journal: ESMO Open

Article Title: European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis

doi: 10.1136/esmoopen-2019-000606

Figure Lengend Snippet: Effects table for midostaurin in adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM-AHN) or mast cell leukaemia (MCL) (study D2201; cut-off date: 1 December 2014)

Article Snippet: Midostaurin is a multitarget receptor tyrosine kinase inhibitor ( ).

Techniques: Modification